At its Pharma Day, Swiss pharmaceutical giant Roche Holdings AG (OTC:RHHBY) outlined five priority therapeutic areas: neurology, oncology and hematology, immunology, ophthalmology, and cardiovascular, ...

A Roche obesity drug designed to hit two targets led to weight loss that is competitive with other drugs in its class, but from a development standpoint, the drug candidate still trails rival ...

Roche is expanding its scope to a promising but competitive new obesity target, committing $1.65 billion up front to partner on a clinical-stage Zealand Pharma molecule with the potential to be a ...

Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma ...

Roche and Zealand Pharma in March struck a deal worth up to $5.3 billion to co-develop and co-commercialize amylin analog petrelintide as a potentially "next generation" weight loss drug. Executives ...

LONDON, Sept 22 (Reuters) - Swiss drugmaker Roche (ROG.S), opens new tab signalled its ambition to join Eli Lilly and Novo Nordisk at the top of the booming weight-loss market on Monday, as it ...

Charles R. Goulding and Aaron Rofe... reveal how overlooked incentives can quietly turn everyday operations into major savings.

Following the apparent elimination of a late-stage gene therapy study last week, Swiss drug juggernaut Roche has confirmed that it’s axing a hemophilia candidate inherited in its 2019 buyout of Spark ...